• Newsletter

    Welcome our newly joined Editorial Board Members

    We are very pleased to release the news that six outstanding experts in the field (mainly from genetics, lymphoma, neuro oncology, gynecological oncology, liver cancer, etc.) have joined the Editorial Board of ETAT journal since August 2020. Their recognition and support will be always remembered and appreciated greatly. We warmly welcome their participation and look forward to developing the journal to the next level together.


    Associate Editors:
    Prof. Francesco Bertoni, MD
    Head of Lymphoma Genomics, deputy director of Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. Vice-president of SAKK Project Group Lymphoma.


    Prof. Antonio Giordano, MD, PhD
    Present Professor, Department of Biology and Medicine; Present Director, Sbarro Health Research Organization; Present Director, Center of Biotechnology; Present Director, Professional Master Program (PSM) in Bioinnovation; Temple University, Philadelphia, PA, USA. Present “Chiara Fama” Professor, Department of Medical Biotechnology, University of Siena, Italy.


    Prof. Chunsheng Kang, MD, PhD
    Deputy Director of Tianjin Neurology Institute, Director of neuro-tumor laboratory of Tianjin Medical University General Hospital, Tianjin, China. Vice Chairman of Glioma Committee of the Chinese Medical Doctor Association, Chairman of the 2nd Basic and Transfer Chemistry Group, and Permanent Member of Glioma Committee of the Chinese Anti-Cancer Association.


    Prof. Maurie Markman, MD
    President, Cancer Treatment Centers of America Medicine & Science; Chief Clinical Officer, CTCA Health, Philadelphia, PA, USA.


    Prof. Massimo Di Maio, MD

    Director, Division of Medical Oncology, A.O. Ordine Mauriziano; Associate Professor of Medical Oncology, Department of Oncology, University of Turin, Torino, Italy.


    Editorial Board Member:
    Prof. Lorenza Rimassa, MD

    Associate Professor of Medical Oncology, Department of Biomedical Sciences, Humanitas University; Deputy Director, Medical Oncology Unit, Humanitas Cancer Center, Humanitas Research Hospital, IRCCS, Milano, Italy. Member of the Italian Association of Medical Oncology (AIOM), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Association for the Study of the Liver (EASL), and the International Liver Cancer Association (ILCA).

    Sep. 7, 2020

    A warm welcome to our new Associate Editor: Prof. Francesco Bertoni

    We are so excited to announce that Prof. Francesco Bertoni has joined our journal as the Associate Editor. Prof. Bertoni focuses on the research of the development of new anti-lymphoma compounds and lymphoma genomics, is the head of Lymphoma Genomics, deputy director of Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland, and the Vice-president of SAKK Project Group Lymphoma.


    Aug. 27, 2020

    ETAT listed in "Journals stating that they follow the ICMJE Recommendations"

    Exploration of Targeted Anti-tumor Therapy always endorses and applies the standards and recommendations of the ICMJE, to ensure the rigorousness of review and publication process. Now, the journal has been recognized in the list of "Journals stating that they follow the ICMJE Recommendations". Learn more about the information via http://www.icmje.org/journals-following-the-icmje-recommendations/.


    Aug. 27, 2020